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Abstract 
Background: Cognitive deficits are well documented in ecstasy (MDMA) users with such 
deficits being taken as evidence of dysregulation of the 5HT system. More recently 
neuroimaging has been used to corroborate these deficits. The present study aimed to assess 
multitasking performance in ecstasy polydrug users, polydrug users and drug naïve 
individuals. It was predicted that ecstasy polydrug users would perform worse than nonusers 
on the behavioural measure and this would be supported by difference in cortical blood 
oxygenation. Methods: Twenty ecstasy-polydrug users, 17 polydrug users and 19 drug naïve 
individuals took part. On day 1 drug use history was taken and questionnaire measures were 
completed. On day 2, participants completed a 20 minute multitasking stressor while brain 
blood oxygenation was measured using functional near infrared spectroscopy (fNIRS). 
Results: There were no significant differences between the 3 groups on the subscales of the 
multitasking stressor. In addition, there were no significant differences on self-report 
measures of perceived workload (NASA – TLX). In terms of mood, ecstasy users were 
significantly less calm and less relaxed compared to drug-naïve controls. There were also 
significant differences at 3 voxels on the fNIRS indicating decreased blood oxygenation in 
ecstasy users compared to drug naïve controls at V2 (left DLPFC), V14 and V16 (right 
DLPFC), and compared to polydrug controls at V14. Conclusions: The results of the present 
study provide support for changes in brain activation during performance of demanding tasks 
in ecstasy polydrug users, which could be related to cerebral vasoconstriction.  
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1. Introduction 
Recreational drug use is argued to be detrimental to normal physiological and 
psychological functioning. Various studies have found cognitive deficits in ecstasy/MDMA 
users (Montgomery et al., 2010; Parrott & Lasky, 1998; Wareing et al., 2004). While some 
studies have shown deficits in executive functioning (Fisk et al., 2004; Montgomery et al., 
2005), a number of recent reviews have shown the most prominent and persistent deficits are 
in learning and memory, particularly verbal recall (Gouzoulis-Mayfrank & Daumann, 2009; 
Kalechstein et al., 2007; Zakzanis et al., 2007). The acute psychological and physiological 
effects are thought to result primarily from serotonin and dopamine agonsim (McDowell & 
Kleber, 1994), with repeated exposure purported to damage serotonin neurons resulting in 
problems with cognition, sleep and mood (Parrott et al., 2000; Parrott, 2013). In animal 
studies MDMA administration mirroring human recreational doses has a deleterious effect on 
serotonergic neurons (Green et al., 1995). Such serotonergic neurotoxicity is a possibility in 
humans, especially with higher nightly doses (McCann et al., 1994). Moreover the neuronal 
areas implicated in working memory and executive functioning are often observed to be 
localised in the dorsolateral pre-frontal cortex (Curtis & D’Esposito, 2003). These structures 
are densely innervated with 5-HT receptors (Pazos et al., 1987), thus serotonergic 
neurotoxicity or down-regulation may result in cognitive deficits specific to functions that 
these areas maintain (Montgomery & Fisk, 2008; Reneman et al., 2006).  
Neuroimaging techniques (EEG, fMRI, fNIRS) are increasingly used in drug research 
to provide neurophysiological correlates of behavioural deficits, or indeed perhaps as a more 
sensitive measure of cognitive impairment. For example Burgess et al. (2011) assessed 
ecstasy users’ performance on verbal and non-verbal recognition memory, with ERP 
measures compared to two control groups (drug naive participants and polydrug users who do 
not use ecstasy). Ecstasy users displayed abnormalities in an ERP component associated with 
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recollection of words but not faces, despite equivalent behavioural performance. Similarly 
Kanayama et al. (2004) observed fMRI differences in cannabis users compared to controls 
during a spatial working memory task despite the absence of behavioural differences. Bosch 
et al. (2013) have also shown a direct link between brain glucose metabolism in the 
dorsolateral prefrontal cortex (DLPFC) and level of MDMA use. MDMA users were 
impaired relative to controls on the Rey Auditory Verbal Learning Test (RAVLT) and 
showed significantly decreased glucose metabolism in various brain areas including the right 
hippocampus, bilateral DLFPC, bilateral thalamus and inferior parietal cortex. In the MDMA 
users, positive correlations were observed between glucose metabolism in the prefrontal and 
parietal areas and RAVLT performance. Importantly, lifetime MDMA dose was significantly 
negatively related to glucose metabolism in the left DLPFC. These studies highlight the 
importance of investigating brain indices of cognitive performance in addition to behavioural 
indices.  
The present study employed Functional Near-Infrared Spectroscopy (fNIRS). fNIRS 
is a novel, non-invasive, optical neuroimaging technique that is portable and is used to 
measure the haemodynamic response to brain activation (Leff et al., 2011). Typically fNIRS 
will penetrate to structures around 2-3 mm of the cortex underlying the skull (Firbank et al., 
1998). Therefore forebrain structures such as the DLPFC can be easily accessed and observed. 
Activation of the DLPFC is prominent in higher level processing, and due to these structures 
being easy to access with this type of imaging, it has been used in several studies observing 
motor control and learning (Leff et al., 2011), as well as more complex tasks that involve 
working memory and category discrimination (Izzetoglu, 2004). Generally an increase in the 
chromophore Hbo2 (oxyhaemoglogin) coupled with a decrease in Hhb (deoxyhaemoglobin) 
is accepted as being reflective of activation to a certain brain region (Ehlis et al., 2008; Leff 
et al., 2008 Leff et al., 2011) and the distribution of this response is regionally specific; thus 
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the cortical regions underlying certain optodes of the fNIRS headset are understood to be 
responsible for the observed response (Leff et al., 2011).  
Although currently there remains a paucity of studies conducted with fNIRS and 
substance use (specifically ecstasy/MDMA use), it has been used in other populations with 
working memory problems. Ehlis et al. (2008) observed a significant reduction in Hbo2 over 
ventrolateral prefrontal cortex channels in ADHD patients compared to controls in relation to 
a working memory N-back task. It was argued this reflects a reduction in activation of this 
area of the brain during task performance. Interestingly this was not accompanied by 
significant behavioural differences (although a trend was observed). Similarly Schecklmann 
et al. (2008) report lower concentration of Hbo2 in ADHD patients relative to controls during 
two versions of a verbal fluency task, suggesting that executive functioning deficits are 
associated with decreased oxygenation to the brain areas that underlie performance of these 
tasks. 
The present study aims to investigate changes in prefrontal blood oxygenation in 
response to a demanding task in ecstasy users, polydrug users and nonusers. The cerebral 
hemodynamic response to conducting several tasks at once will be measured as well as 
behavioural performance. It is hypothesised that ecstasy users will perform worse on the 
multi-tasking stressor and fNIRS will provide corollary data of this by displaying a reduction 
in oxygenated haemoglobin in comparison to the control groups. 
2. Method: 
2.1 Design: 
For behavioural and fNIRS analysis a between groups design was used, with a between 
groups factor of drug user group with 3 levels (ecstasy user, polydrug user and drug naïve 
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controls. Univariate ANOVA was conducted on the behavioural data with the total scores on 
each component of the task as the dependent variables (Stroop, mental arithmetic, 
tracking/target area – visual monitoring and warning/rising bars – visual monitoring). fNIRS 
data was analysed using univariate ANOVA with mean oxygenated haemoglobin at each 
voxel measured as the dependent variables (voxels 1-16). Any significant main effects were 
further investigated using Tukey’s HSD.  
2.2 Participants: 
Twenty ecstasy users (mean age: 21.61±0.52; 12 male), 17 non-ecstasy-polydrug user 
controls (mean age: 21.23±0.79; 12 male) and 19 drug naïve controls (mean age: 21.60±0.84; 
6 male) were recruited via direct approach to Liverpool John Moores University students. For 
inclusion in the study participants had to be aged between 18 – 29 years. For inclusion in the 
ecstasy/MDMA user group, participants must have used ecstasy/MDMA on at least 5 
occasions over their lifetime (actual minimum = 7 tablets) but may have used a range of 
substances in addition to MDMA. To be included in the non-ecstasy polydrug user group, 
participants must have consumed illicit drugs on at least 3 occasions in the last 12 months, 
but never have consumed ecstasy/MDMA, and finally for inclusion in the drug naïve control 
group participants must have never consumed any illicit drugs. All participants were asked to 
abstain from consuming ecstasy for a minimum of 7 days prior to testing. Participants were 
also requested to abstain from use of other illicit drugs for a minimum of 24 hours prior to 
participating and ideally 7 days. 
2.3 Materials 
A background drug use questionnaire (Montgomery et al., 2005) was administered. Estimates 
of total lifetime drug use of each drug were calculated (as per Montgomery et al., 2005) as 
well as totals for last 30 days drug use and weekly drug use estimates.  
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The SAI VAS (State Anxiety Inventory – Visual Analogue Scale) was completed pre and post 
testing period, this comprises 6 statements (I feel calm, I feel tense, I feel upset, I feel relaxed, 
I feel content, I feel worried) and participants have to indicate on a 100mm line how much 
they agree with the statement, ranging from 0 – not at all, to 100 – very much.  
Multitasking stress test 
The multi-tasking framework (Purple Research Solutions, UK) is a PC ran platform used to 
elicit acute psychological stress (Wetherell & Sidgreaves, 2005). The same combination of 
four stressor modules (Stroop, mental arithmetic, tracking/target area – visual monitoring and 
warning/rising bars – visual monitoring) was used for all participants, at a medium intensity 
workload. The task requires participants to attend to the 4 different components/modules of 
the task simultaneously. The set of tasks include a mental arithmetic task whereby 
participants are required to calculate a series of 2 x 3 digit addition sums; visual monitoring 
(target area) whereby participants must monitor the position of a moving cursor and reset this 
cursor when it enters a points zone; a second visual monitoring module (rising bars) 
comprises of a set of 6 bars that rise towards a target line at varying speeds. Once the bars 
have reached the target, participants must select the order of which the bars reached the target, 
fastest first; and finally a Stroop task module involves colour names appearing onscreen in 
various colours, participants must correctly select the colour the word appears in, rather than 
the written word. For more information on the different modules of the framework, see 
Wetherell and Sidgreaves (2005).  
Equipment 
Haemodynamic response to task was monitored using a continuous wave fNIRS system 
developed by Drexel University (Philadelphia, PA) and supplied by Biopac systems (Goleta, 
CA, USA). The fNIR sensor has a temporal resolution of 500ms per scan (2Hz), with a 
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source-detector separation of 2.5cm allowing 1.25cm penetration depth (Ayaz et al., 2012). 
An fNIR100 control box and data acquisition and visualisation software COBI studio (Drexel 
university) were used during data collection (as per Ayaz et al., 2011; Ayaz et al., 2012) with 
a serial cable between display and acquisition PCs to identify task markers.  
2.4 Procedure 
Participants were required to attend the lab on 2 occasions. On Time 1, upon entering the lab 
participants were informed of what the study would entail and written consent was obtained. 
Participants were given the background drug use questionnaire and an assessment of fluid 
intelligence (Raven’s Progressive Matrices- RPM Raven et al., 1998) to complete. On Time 2, 
a pre-task SAI-VAS was given upon entering the lab. After this the fNIRS sensor pad was 
attached to the participants’ forehead whilst they read instructions on how to complete the 
task. Participants then completed an easy two minute practise trial of the task. The fNIRS 
signals were displayed on a desktop computer running COBI studio (Drexel University) in an 
adjacent room to the testing room. Providing the signals from the fNIRS were stable, a 
baseline of inactivity was recorded before the participants were instructed to complete a 20 
minute session of the multi-tasking stressor task on a desktop computer running the purple 
framework (Purple Solutions, UK). After the 20 minutes had elapsed, participants completed 
a post task SAI-VAS. The NASA TLX (Task Load Index - Hart et al., 1988) was completed 
post task to measure perceived workload. Finally, participants were debriefed and paid £20 in 
store vouchers. The study was approved by Liverpool John Moores University Research 
Ethics Committee, and was administered in accordance with the ethical guidelines of the 
British Psychological Society. 
2.5 fNIRS Analysis 
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fNIRS raw data from COBI studio was pre-processed using fnirSoft (Ayaz, 2010). All 16 
optodes (oxy and deoxy haemoglobin) were visually inspected for any saturated channels, 
and any saturated channels were discarded. A high-pass filter (0.1Hz cut off) and a linear 
phase filter (order of 20) were used to remove high frequency noise and noise due to 
respiration (Ayaz et al., 2011; Ayaz et al., 2012). Using the modified Beer-Lambert law 
logarithm in fnirSoft (Ayaz, 2010), we calculated total blood oxygenation, deoxygenation and 
volume changes relative to baseline over the entire epoch for the 16 channels.   
3. Results 
RPM scores and pre and post task SAI-VAS scores are displayed in Table 1.  Indices of other 
drug and alcohol use are displayed in Table 2.  
<<Insert Tables 1 & 2 Here>> 
One way ANOVA revealed that there were no significant between group differences on age 
and fluid intelligence (p>.05 in both cases). Pre and post task SAI-VAS scores for each of the 
six subscales (calm, tense, relaxed, content, upset and worried) were analysed using a mixed 
ANOVA, with user group as the between subject factor and timepoint (pre/post) as the within 
subjects factor. For calm there was no significant main effect of time point F(1, 53)=0.19, 
p>.05 and no time point by group interaction F(2, 53)=1.97, p>.05, but there was a main 
effect of group F(2, 53)=3.08, p≤.05. Pairwise comparisons showed that ecstasy users felt 
less calm than both other groups (p<.05). For tense there was a significant main effect of time 
point F(1, 53)=3.95, p ≤ .05, with ecstasy and polydrug users showing increases at Time 2, 
but no timepoint by group interaction F(2, 53)=0.32, p>.05, and no main effect of group F(2, 
53)=1.75, p>.05. Upset showed no main effect of timepoint F(1, 53)=1.69, p > .05, no 
timepoint by group intereaction F(2, 53)=1.82, p > .05 and no main effect of group F(2, 
53)=0.07, p > .05. Relaxed also showed no main effect of time point F(1, 53)=0.03, p > .05 
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and no timepoint by group interaction F(2, 53)=0.05, p > .05, but does show a significant 
main effect of group F(2, 53)=3.04, p≤.05. Pairwise comparisons revealed that drug naïve 
controls were significantly more relaxed than ecstasy users (p<.05). Content revealed no 
significant effect of timepoint F(1, 53)=0.25, p > .05, no timepoint by group interaction F(2, 
53)=0.33, p > .05, and no main effect of group F(2, 53)=1.39, p > .05. Finally, worried 
revealed a main effect of timepoint F(2, 53)=3.04, p≤.05, with worry being greatest pre task, 
but no timepoint by group interaction F(2, 53)=0.27, p > .05, and no main effect of group F(2, 
53)=1.06, p > .05. 
ANOVA revealed a between group difference in the amount of alcohol consumed 
(weekly) F(2, 52)=3.28, p<.05. Pairwise comparisons revealed that the ecstasy users drank 
significantly more than drug naive controls p ≤ .05.  
 
3.1 Behavioural Data  Analysis 
The multi-tasking stressor task was developed by purple solutions (Purple research solutions, 
UK) and performance was analysed using SPSS (17). Due to 8 participants (4 ecstasy users, 3 
polydrug users and 1 drug naïve control) not following instructions correctly on the Stroop 
task and consistently answering incorrectly on the task, their data on this component on the 
task was not analysed any further. These participants are also excluded from fNIRS analysis. 
Performance data can be observed in Table 3 
<<Insert Table 3 About Here>> 
There were no significant differences between groups on any of the components of 
the task; Stroop F(2,45)=0.08, p>.05; Maths F(2,53)=0.56, p>.05; Tracking/target visual 
monitoring F(2,53)=0.50, p>.05. Levene’s statistic was violated on the warning/rising bars 
scores, therefore an independent samples Kruskall-Wallace test was conducted. This revealed 
that there were no significant differences between ecstasy users (rank = 560), polydrug 
11 
 
controls (rank = 570) and drug naïve controls (rank = 580) on this component of the task; 
(H(2) =1.43, p>.05). On the composite total score, ANOVA revealed no significant between 
group differences F(2,45)=0.55, p>.05. 
  Post task NASA TLX scores were analysed using MANOVA. This revealed no 
overall between group differences in task load F(12,96)=1.25, p>.05 for Pillai’s trace, nor 
any between group differences on the individual sub-scales (Mental demand; F(2,52)=1.32, 
p>.05, Physical demand; F(2,52)=0.11, p>.05, Temporal demand; F(2,52)=0.10, p>.05, 
Effort; F(2,52)=1.97, p>.05, Performance; F(2,52)=2.39, p>.05, Frustration; F(2,52)=2.65, 
p>.05). 
3.2 fNIRS Analysis 
Averaged oxygenated and deoxygenated haemoglobin changes from baseline are 
displayed Figures 1 and 2. A series of ANOVAs1 were used to assess group differences in 
changes from baseline. This analysis was conducted due to large concentration increases in 
oxygenated haemoglobin and decreases in deoxygenated haemoglobin being understood to 
represent increased levels of neurological activation (Hoshi et al., 2001; Cui et al., 2010; 
Ayaz et al., 2011; ) and also due to each voxel theoretically relating to a different brain 
region.  
<<Insert Figures 1 & 2 About Here>> 
ANOVA revealed significant between group differences in average oxy-Hb changes 
at voxel 2 F(2,43)=4.78, p<.05; V14 F(2,43)=6.37, p<.01 and V16 F(2,42)=3.32, p<.05. 
There were no significant between group differences at any of the other voxels measures 
(p>.05).  
                                                 
1 Due to small amounts of missing data on different optodes, MANOVA was not appropriate for this analysis.  
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 Pairwise comparisons revealed that at V2 ecstasy users showed a significantly 
reduced oxy-Hb change compared to drug naïve controls (p<.05). At V14 ecstasy users show 
significantly lower oxy-Hb than both polydrug controls (p<.01) and drug naïve controls 
(p<.05). At V16 ecstasy users again show significantly lower oxy-Hb than drug naïve 
controls (p<.05).    
ANOVA on deoxy-Hb changes from baseline revealed significant between group 
differences at V1 F(2,42)=3.96, p<.05, V2 F(2,43)=4.71, p<.05, V4 F(2,30)=3.66, p<.05, 
V12 F(2,30)=5.04, p<.05 and V14, F(2,43)=5.09, p<.01. There were no significant between 
group differences at any of the other voxels measured (p>.05). 
 Pairwise comparisons revealed that at V1, polydrug controls showed significantly 
greater deoxy-Hb than drug naïve controls (p<.05), and this difference approached 
significance compared to ecstasy users (p=.07). At V2, polydrug controls showed 
significantly greater deoxy-Hb increase than ecstasy users (p<.05) and this difference 
approached significance compared to drug naïve controls (p=.08). At V4 polydrug controls 
showed significantly increased deoxy-Hb compared to drug naïve controls (p<.05). At V12 
polydrug controls showed significantly increased deoxy-Hb compared to both ecstasy users 
and drug naïve controls (p<.05 in both cases) and at V14 polydrug controls showed 
significantly greater deoxy-Hb compared to ecstasy users (p<.01). Ecstasy users and drug 
naïve controls did not differ significantly from each other at any of these voxels. 
 These results show a general blunted increase in oxygenated haemoglobin during the 
tasks for ecstasy users relative to drug naive controls at voxels 2, 14 and 16. Ecstasy users 
also displayed significantly reduced oxy-Hb change at V14 compared to polydrug controls. 
Furthermore, as to be expected due to a general inverse correlation between oxygenated and 
deoxygenated haemoglobin usually observed in neurological activity, ecstasy users have 
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shown a significantly reduced decrease in deoxygenated haemoglobin compared to drug 
naïve controls at V1,  and relative to polydrug controls at V2, V12 and V14. 
Relationship between cortical blood changes and drug use.  
To assess the relationship between the changes in cortical blood flow observed using fNIRs 
and parameters of drug use, we used Spearman’s correlations. Results are displayed in Table 
4; all correlations are evaluate at p<.01 to adjust for multiple comparisons. 
<<Insert Table 4 About Here>> 
There were a number of significant correlations between ecstasy use and oxygenation change. 
Notably, frequency of use was significantly correlated with V2 (left inferior DLPFC), 6 & 8 
(left inferior mid PFC) and 14 (right inferior DLPFC), total lifetime dose with V2 (left 
inferior DLPFC), 6 & 8 (left inferior mid PFC) and 14 & 16 (right inferior DLPFC), while 
amount used in the last 30 days was significantly correlated with V2 & 4 (left inferior 
DLPFC), 8 (left inferior mid PFC) and 14 & 16 (right inferior DLPFC). There were 2 
significant correlations with indices of drug use, with frequency of cannabis use correlated 
with V8 and frequency of cocaine use with V14. In both cases the correlations were weaker 
than those for ecstasy. For deoxygenation change, total lifetime dose of ecstasy was 
significantly correlated with V14 (right inferior DLPFC).  
 
4. Discussion 
The aim of the current study was to investigate the effects of ecstasy use on a 
multitasking stress test and to assess drug related differences in haemodynamic response to 
task. The ecstasy users in this study did not differ significantly from controls on background 
variables such as perceived stress, fluid intelligence or age. Nor did they differ significantly 
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on any of the individual components that made up the multi-tasking stressor task, or on 
perceived workload as measured by the NASA TLX. There were however differences on 
subscales of the SAI VAS, indicating that ecstasy users felt less calm than both other groups 
overall and less relaxed than drug naïve controls. Furthermore, as to be expected, all groups 
were less worried post task.   
Despite an absence of between group differences on behavioural measures, the fNIRS 
data revealed several significant differences that are worthy of discussion. Ecstasy users 
displayed a significant reduction in oxygenated haemoglobin compared to both polydrug 
users and drug naive controls at voxel 14 pertaining to the inferior side of the right DLPFC. 
At voxels 2 and 16, ecstasy users had significantly smaller change in oxygenated 
haemoglobin relative to drug naïve controls. V2 related to the inferior side of the left DLPFC, 
and V16 relates to the inferior side of the right DLPFC. As such the results imply reduced 
activation of the dorsolateral prefrontal cortex in ecstasy users that is bilateral. A blunted 
decrease of deoxygenated haemoglobin in ecstasy users compared to drug naive controls V1 
and relative to polydrug controls V2 and V12 are also suggestive of similar differential 
functioning between ecstasy users and controls over the left DLPFC area. Furthermore V12 
pertains to the right medial PFC, suggesting that MDMAs effects on haemodynamic response 
are apparent across several areas of the PFC. In addition to these between group differences, 
indices of ecstasy use were significantly correlated with oxygenation change in the right and 
left inferior DLPFC and the inferior mid PFC. These correlations were negative, suggesting 
that more frequent ecstasy use, a higher lifetime dose and a larger amount used in the 30 days 
prior to testing were associated with a smaller oxygenation change from baseline.    
In animal studies it is well documented that MDMA is a selective brain serotonin 
neurotoxin (Green et al., 2003). Moreover the DLPFC is densely innervated with 5HT 
neurons (Curtis & D’Esposito, 2003) and if MDMA is also a selective serotonin neurotoxin 
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in humans, then differential functioning of areas of the DLPFC and the cognitive processes 
maintained by these areas should be observable in ecstasy users. In line with this, the current 
results suggest a differential pattern of cognitive function in ecstasy users relative to controls 
that relate to areas of the DLPFC. Similar findings from other neuroimaging studies have also 
suggested impairment in ecstasy users that are localised to areas of the PFC. Jager et al. 
(2008) observed altered brain activity patterns in relation to associative learning in the left 
DLPFC as well as the right middle occipital gyrus in an fMRI study. Although, it was 
conceded that this does not necessarily signify serotonergic neurotoxicty, it does, however, 
go some way to substantiating the idea of widespread loss of serotonin axons with repeated 
use of MDMA. Moreover, serotonergic modulation of the DLPFC has been observed in a 
tryptophan depletion study with fMRI (Evers et al., 2005), where it was observed that 
behavioural reversal after tryptophan depletion was accompanied by changes in signals 
presenting from the right ventro medial PFC, as well as the dorsomedial prefrontal cortex. 
More recently Bosch et al. (2013) have linked brain glucose metabolism in the dorsolateral 
prefrontal cortex (DLPFC) to level of MDMA use, with higher use being associated with 
lower levels of glucose metabolism. MDMA users had dysfunction in glucose metabolism in 
a range of brain areas which is consistent with serotonergic neurotoxicity; specifically the 
decreases in the raphe nuclei, where serotonergic neurons stem from, provide corollary 
evidence of neurotoxicity/short term degradation.  
This suggests that performance on cognitive tasks can be altered by transient 
depletion of serotonin in brain regions, such as the DLPFC that relate to higher level 
cognitive tasks, such as reversal learning.  
Other support for serotonergic neurotoxicity following ecstasy use in humans comes 
from Kish et al. (2010) who report significantly decreased serotonin transporter binding in all 
cerebral cortices and the hippocampus and the decrease related to amount of drug use. 
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Similar decreases in SERT binding in ecstasy users were reported by Erritzoe et al. (2011) in 
a PET study. Moreover Benningfield and Cowan (2013) reviewed recent studies in to brain 
imaging in ecstasy users and concluded that recreational ecstasy use in humans is associated 
with increases in the 5HT-2A receptors and decreases in SERT. These findings suggest the 
neurotoxic potential of ecstasy, and given that behavioural studies have reported performance 
deficits in executive functioning tasks that are maintained by areas highly populated with 
5HT neurons, evidence is growing to suggest possible serotonergic neurotoxicity in the 
prefrontal cortex. This idea is further corroborated by the current study, with the observation 
of a differential pattern of functioning in these areas in ecstasy users. It is important to note 
that the direction of oxygenation change is not as predicted. One possible reason for this may 
be related to the sympathomimetic effect of ecstasy. A number of previous studies have noted 
increased vasoconstriction in human ecstasy users not only while on drug, but for prolonged 
periods of abstinence. Chang et al. (2000) found protracted vasoconstriction evidenced by 
decreases in regional cerebral blood flow (rCBF) in dorsolateral areas of the PFC. In addition, 
Reneman et al. (2000) noted that reduced serotonergic binding in a SPECT study was 
significantly correlated with rCBF, with low CBF (indicating vasoconstriction) associated 
with low binding. Taussky et al. (2012) found a strong linear relationship between fNIRS 
measurements and rCBF measurements taken via perfusion CT scanning suggesting that 
fNIRS measurements may be sensitive to the same changes in neuromicrovasculature. Taken 
together, one possible reason for the reduction in oxygenation in ecstasy users is that damage 
to the serotonin system has caused prolonged vasoconstriction resulting in decreased rCBF in 
frontal areas. Consequently the change in oxygenation is less pronounced as there is less 
blood flow altogether.  
The DLPFC is implicated in higher level cognitive functioning, and behavioural 
studies have shown that ecstasy users’ performance on tasks that load on higher level 
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executive functions such as memory updating is reduced relative to controls (Montgomery & 
Fisk, 2008). Moreover ecstasy related cognitive deficits have been observed to be increased 
with task/cognitive load (Fisk et al., 2011). As such the current study is in line with previous 
findings of ecstasy users showing cognitive deficits with increased workload, as the 
multitasking paradigm loads heavily on cognitive functions and alterations to normal 
functioning of areas of the DLPFC have been observed. The Multitasking Framework used in 
the present study required participants to perform several demanding cognitive tasks 
simultaneously. It has been shown to elicit subjective stress in nonusers (Wetherell and 
Sidgreaves, 2005). To further support this, Wetherell et al. (2012) found that recreational 
Ecstasy/MDMA users perceive significantly greater time pressure and levels of mental effort 
compared to non-user controls, during the multitasking framework. It is also noteworthy that 
7 of the 8 participants’ data that was excluded from analysis of the Stroop task module, due to 
incorrect interpretation of instructions were drug users (4 ecstasy users).  It has been observed 
previously that ecstasy users made more errors when completing a web based questionnaire 
(Rodgers et al., 2003) than other drug users and drug naïve controls. Therefore it is possible 
that there are deficits in the processing of instructional information associated with ecstasy 
use. 
 Functional near infrared spectroscopy, due to its specificity to the pre frontal cortex, is 
useful for studies in ecstasy users as it is these frontal structures that are densely innervated 
with 5HT neurons and are perhaps most susceptible to degradation with ecstasy use. However 
the level of demand and relatively high mental workload involved in the multi-tasking 
paradigm could require recruitment of additional brain areas that are currently not monitored 
with this device (Ayaz, et al., 2012). Perhaps if this equipment enabled coverage of the whole 
brain, or indeed it was accompanied by other neuroimaging techniques such as fMRI a better 
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understanding of the underlying mechanisms could be achieved. Future research should seek 
to clarify the nature of these changes in the brain, in the absence of behavioural differences.   
Although there are significant findings in the current study in relation to ecstasy users’ 
cerebral blood flow, as with any study pertaining to cognitive deficits and ecstasy use certain 
limitations require a degree of caution when interpreting results. Attempts were made to 
control for use of other drugs with an inclusion of a polydrug user group (namely cannabis 
users) that were ecstasy naïve. However, the ecstasy group used a range of other drugs and as 
such it is still possible that any observed differences could be attributable to other drug use, 
or perhaps concomitant use of other drugs with ecstasy.  Nevertheless, the results from 
pairwise comparisons did show a differential pattern of DLPFC activation in ecstasy users 
compared to both control groups, which suggests cognitive impairment is observable in 
ecstasy using populations. It should also be noted that while the multitasking framework is a 
good task for eliciting high mental effort and psychological/psychobiological indices of stress, 
multitasking as a function may be less reliant on 5HT compared to other cognitive functions 
such as verbal recall (Robbins & Arnsten, 2009). Future research should seek to investigate 
fNIRS parameters of performance utilising verbal recall tasks.  
The necessity of a quasi-experimental design in this study can also be considered a 
limitation and the possibility that some other individual differences, besides drug use, may be 
responsible for the effects observed here cannot be ruled out  (although, we have attempted to 
control for many of these, including fluid intelligence and perceived workload). Furthermore, 
self reports of background drug use are problematic due to recall of quantities and 
frequencies etc. not being entirely accurate, not least given the implications for memory 
deficits with drug use. However due to the legal status of the drug being investigated, this is 
the most appropriate method for attaining an estimate of lifetime drug use and is the most 
commonly used method in the literature investigating drug use and cognition (Fox et al., 
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2001; Montgomery et al., 2005; Montgomery et al., 2010). Additional uncertainty about 
purity of ecstasy tablets consumed, as well as cocaine purity and cannabis strength cannot be 
assured. However, ecstasy tablets collected from amnesty bins in nightclubs in the UK have 
been reported to be approaching 100% purity (Parrott, 2004). Nevertheless if this is incorrect 
and the purity is, in fact,  much lower, then perhaps magnitude of cognitive effects observed 
is even more concerning (Montgomery et al., 2010). In the present study, resources limited us 
to subjective confirmation of drug use and abstinence, and we concede that an objective 
measure would be advantageous (e.g. from hair or urine samples). Reliance on self-report 
measures of drug use is common in this field of research, and there are many published 
studies that do not report objective measures (e.g. Fox et al, 2002; Montgomery et al. 2005; 
Rodgers, 2000).  A comparison of subjective vs. objective measures of drug use (Scholey et 
al., 2011) has recently shown that self-reports of ecstasy use  are consistent with objective 
analysis of hair samples in ecstasy users. More recently, research from our own laboratory 
suggests that participants are adhering to our inclusion criteria of drug abstinence (Roberts et 
al., 2013a; Roberts et al., 2013b); very low levels of metabolites were found in the urine of 
recent users and excluding these participants from analysis did not affect the results. Thus 
while we have no reason to believe that sub-acute intoxication would affect the results of the 
present study, future research should seek to utilise an objective measure of drug use 
The present study provides evidence of aberrant neural functioning, in ecstasy 
polydrug users, in relation to DLPFC oxygenated and deoxygenated haemoglobin.  
Reductions in the increase of oxygenated haemoglobin to the inferior right DLPFC, as well as 
left inferior DLPFC, during a task that requires a high mental workload suggest that ecstasy 
users have changes in these networks that support higher level cognitive functioning. These 
changes may be attenuating any observable behavioural differences. These findings are in 
20 
 
line with the literature suggesting such changes in blood flow may be due to serotonergic 
neurotoxicity in forebrain structures. 
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Table 1 –Fluid intelligence and mood variables 
 Ecstasy Users 
 
Polydrug  Drug Naïve  
 Mean SD Mean SD Mean SD 
Ravens Progressive Matrices 
(No correct: maximum 60) 
49.70 5.12 51.82 5.42 49.58 6.94 
 
SAIVAS pre calm 
 
SAIVAS post calm 
 
SAIVAS pre tense 
 
SAIVAS post tense 
 
SAIVAS pre upset 
 
SAIVAS post upset 
 
SAIVAS pre relaxed 
 
SAIVAS post relaxed 
 
SAIVAS pre content 
 
SAIVAS post content 
 
SAIVAS pre worried 
 
SAIVAS post worried 
 
63.80 
 
70.00 
 
20.30 
 
25.10 
 
11.70 
 
12.50 
 
66.05 
 
64.30 
 
71.60 
 
71.25 
 
22.40 
 
19.70 
 
24.25 
 
17.27 
 
15.89 
 
15.97 
 
9.59 
 
9.55 
 
20.35 
 
17.93 
 
16.54 
 
11.84 
 
17.27 
 
12.68 
 
 
84.06 
 
74.24 
 
15.71 
 
22.35 
 
14.65 
 
8.00 
 
68.29 
 
69.00 
 
76.76 
 
82.00 
 
19.12 
 
13.71 
 
10.29 
 
30.68 
 
19.09 
 
24.89 
 
23.17 
 
9.97 
 
28.76 
 
29.54 
 
21.33 
 
14.90 
 
24.76 
 
17.75 
 
79.00 
 
78.37 
 
16.14 
 
14.32 
 
11.00 
 
10.37 
 
79.47 
 
78.89 
 
74.21 
 
73.89 
 
14.79 
 
12.37 
 
19.44 
 
20.28 
 
16.84 
 
16.24 
 
11.69 
 
10.65 
 
16.52 
 
16.70 
 
24.67 
 
21.21 
 
17.69 
 
13.80 
 
 
  
27 
 
Table 2: Indices of drug use.  
Frequency: times per week.  
Units of total use and recent use (last 30 days): ecstasy (tablets); cannabis (joints); Cocaine, amphetamine, 
ketamine, mephedrone (grams); Alcohol (UK units).   
 Ecstasy user Polydrug Drug Naive 
 Mean SD n Mean SD n Mean SD n 
Ecstasy          
Frequency  0.22 0.21 20 - - - - - - 
Last 30 days  2 3.42 20 - - - - - - 
Total use  
 
253.86 376.20 20 - - - - - - 
Cannabis          
Frequency  2.74 2.81  20 1.11 1.56 16 - - - 
Last 30 days  46.56 59.89 17 19.34 46.36 16 - - - 
Total use  3613.80 4469.70 20 1562.96 3021.05 17 - - - 
          
Cocaine           
Frequency  0.06 0.08 2 0.05 0.06 2 - - - 
Last 30 days  0.00 0.00 2 0.00 0.00 2 - - - 
Total use  415.00 43.84 2 7.50 0.71 2 - - - 
          
Ketamine          
Frequency  0.19 0.19 5 - - - - - - 
Last 30 days  0.00 0.00 5 - - - - - - 
Total use  21.72 
 
16.90 5 - - - - - - 
Mephedrone          
Frequency  0.21 0.16 4 0.16 0.27 3 - - - 
Last 30 days 0 0 4 0 0 3 - - - 
Total use  
 
63.45 57.60 4 23.67 17.39 3 - - - 
Amphetamine          
Frequency  0.13 0.09 3 0.04 - 1 - - - 
Last 30 days  0 0 3 0 0 1 - - - 
Total use  
 
14.00 9.64 3 55 - 1 - - - 
Alcohol units 
p/w 
 
13.20 6.68 20 12.44 9.70 16 6.99 8.14 19 
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Table 3: Performance Data (mean and SD) for the 4 tasks. 
 
 
 
Ecstasy users Polydrug controls Drug naïve controls 
 
 
Stroop 
 
 
4443.75 (1653.38) 
 
 
4222.14 (1683.38) 
 
 
4500.28 (2545.14) 
 
 
Warning 
 
 
550.50 (43.71) 
 
 
566.47 (28.93) 
 
 
533.16 (141.07) 
 
 
Tracking 
 
 
392.80 (112.39) 
 
 
437.29 (58.23) 
 
 
386.11 (203.88) 
 
 
Maths 
 
 
Total 
 
 
414.35 (235.65) 
 
 
5847.75 (1721.07) 
 
 
463.65 (230.06) 
 
 
5691.29 (1727.09) 
 
 
371.05 (293.16) 
 
 
6382.22 (2357.42) 
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Table 4: Correlations with indices of drug use.  
 Ecstasy Cannabis Cocaine 
 Freq Total Recent  Freq Total Recent Freq Total 
oxyV1 
-.09 -.16 .03 -.17 -.03 .11 .16 .06 
oxyV2 
-.33* -.36* -.35* -.17 -.14 -.02 .17 .05 
oxyV3 
-.19 -.26 -.15 -.14 -.01 .14 .11 .06 
oxyV4 
-.32 -.22 -.49* .00 .12 .13 .17 .10 
oxyV5 
-.15 -.19 -.17 -.26 -.12 -.00 .11 .03 
oxyV6 
-.34* -.42* -.29 -.13 -.10 .08 .21 .02 
oxyV7 
-.08 -.10 -.11 -.02 .07 .14 .02 -.03 
oxyV8 
-.41* -.45* -.34* -.33* -.26 -.07 .25 .10 
oxyV9 
-.16 -.17 -.19 -.17 -.10 .06 .09 .05 
oxyV10 
-.26 -.27 -.26 -.27 -.12 -.07 .28 .20 
oxyV11 
-.02 -.11 -.04 -.07 .09 .04 .24 .26 
oxyV12 
-.29 -.33 -.33 -.24 -.11 -.10 .23 .18 
oxyV13 
-.12 -.17 -.08 -.08 .05 .15 .12 .13 
oxyV14 
-.42* -.45* -.38* -.27 -.14 -.09 .34* .11 
oxyV15 
-.07 .14 -.09 -.06 .14 .10 .25 .28 
oxyV16 
-.32 -.37* -.32* -.21 -.11 -.04 .21 .02 
 
        
deoxyV1 
-.06 -.06 -.24 .18 .24 .02 .05 .02 
deoxyV2 
-.11 -.19 -.21 .07 .09 -.00 -.08 -.15 
deoxyV3 
.19 .17 .01 .29 .21 .14 -.13 -.20 
deoxyV4 
.02 .07 -.14 .26 .17 .11 -.11 -.17 
deoxyV5 
-.01 .01 -.08 -.07 -.04 -.12 -.05 -.07 
deoxyV6 
-.14 -.18 -.17 .00 -.04 .10 -.07 -.40 
deoxyV7 
.12 .09 -.04 .20 .24 .10 -.07 -.40 
deoxyV8 
.12 .16 -.04 .23 .20 .15 -.08 -.03 
deoxyV9 
-.04 -.07 -.21 .07 .05 -.04 -.06 -.05 
deoxyV10 
.00 .02 -.06 .04 .14 .05 .05 .09 
deoxyV11 
-.15 -.07 -.10 .04 -.01 -.01 .11 .04 
deoxyV12 
.21 -.25 -.10 -.10 .10 -.03 .26 .30 
deoxyV13 
.17 -.11 -.22 .03 -.01 .00 -.03 -.05 
deoxyV14 
-.29 -.35* -.27 -.16 -.08 -.13 .23 .07 
deoxyV15 
-.17 -.15 -.19 .02 .02 -.03 .05 .15 
deoxyV16 
-.09 -.13 -.20 -.05 .04 -.06 .04 .13 
*Correlation significant at p<.01.  
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Figure 1: Mean oxy-Hb change (µmolar) from baseline during multitasking 
 
Fig.1: Depicts mean oxy-Hb change (µmolar) from baseline during the entire multitasking epoch (20 min) for ecstasy users, polydrug controls and drug naïve controls. 
*Indicates a significant difference from polydrug controls at the .05 level, and ** at the .01 level; † indicates a significant difference from drug naïve controls at the .05 level 
and †† at the .01 level. 
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Figure 2: Mean deoxy-Hb change (µolar) from baseline during multitasking 
 
Fig.2: Depicts mean deoxy-Hb change (µmolar) from baseline during the entire multitasking epoch (20 min) for ecstasy users, polydrug controls and drug naïve controls. 
*Indicates a significant difference from polydrug controls at the .05 level, and ** at the .01 level; † indicates a significant difference from drug naïve controls at the .05 level 
and †† at the .01 level. 
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